BIT ! See latest Ann just out to quote.
Scientists demonstrated that Biotron’s p7 inhibitor,
BIT225, is active against HCV genotypes 1, 2, 4,
5 and 6.
Biotron has previously demonstrated that BIT225 is active
against genotypes 1 and 3 but clinical
trials have not yet extended to patients infected with
other strains of the virus.
Managing Director Dr Michelle Miller said that these latest results suggest Biotron’s compound has
pan-genotype activity.
- Forums
- ASX - Day Trading
- daytrading nov 27 morning
daytrading nov 27 morning, page-37
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
HCH
Hot Chili sets up water company as drought racks Chile–but must also build communities a desal plant